Biotech Firms Receive Orphan Drug Designations, Release Clinical Data, Achieve Goals, Enter Acquisitions & Forecast Revenues - Research Report on Aegerion, Oncolytics, Merrimack, Sangamo, and PDL
On September 9, 2013, Oncolytics Biotech, Inc. (Oncolytics) announced final tumour response data from its US Phase 2 single arm clinical trial in patients with squamous cell carcinoma of the lung (SCCLC) using intravenous administration of REOLYSIN in combination with carboplatin and paclitaxel (REO 021). Oncolytics stated that the study enrolled patients with metastatic stage IIIB or stage IV, or recurrent, squamous cell carcinoma of the lung, who were chemotherapy-naïve for their metastatic or recurrent cancer. According to Oncolytics, the analysis examined percent best overall tumour responses between pre-treatment and up to six treatment cycles and revealed that out of 25 evaluable patients who had more than one cycle of therapy, 92% exhibited overall tumour shrinkage. Oncolytics also informed that final progression-free survival and safety data for the study will be reported in late 2013. The Full Research Report on Oncolytics Biotech, Inc. - including full detailed breakdown, analyst ratings and price targets - is available to download free of charge at: [http://www.investorsreports.com/report/2013-09-09/ONCY]
Merrimack Pharmaceuticals, Inc. Research Report
On August 28, 2013, Merrimack Pharmaceuticals, Inc. (Merrimack) announced that it has reached its enrollment goal in the NAPOLI-1 trial, a randomized Phase 3 study of MM-398, with or without 5-fluorouracil (5-FU) and leucovorin (LV), versus 5-FU and LV, in patients with metastatic pancreatic cancer previously treated with gemcitabine-based therapy. Eliel Bayever, M.D., Vice President of Merrimack and Medical Director of MM-398 said, "To our knowledge this is one of the largest controlled studies ever conducted in this patient population, which has very few treatment options." The Full Research Report on Merrimack Pharmaceuticals, Inc. - incPage: 1 2 3 4 5 Related biology technology :1
. GenWay Biotech Launches New Cardiovascular Diagnostic Blood Test at American Heart Association Scientific Sessions 20112
. Puma Biotechnology Announces Completion of Private Placement3
. Animal Biotechnology - Technologies, Markets and Companies4
. AtheroNova and Maxwell Biotech Group Ratify Agreement to Develop New Atherosclerosis Drug5
. The European Union Signs Grant Contract to Fund a 2 Million Euro Biotechnology Research Project Led by Hadassah College Jerusalem6
. Janssen Biotech, Inc. Announces Collaborative Development and Worldwide License Agreement for Investigational Anti-Cancer Drug, PCI-327657
. Puma Biotechnology Announces Positive PB272 (Neratinib) Phase II Data at CTRC-AACR San Antonio Breast Cancer Symposium8
. Metamark Genetics Signs Collaboration Agreement on Novel Therapeutic Targets with Janssen Biotech9
. SuperNova Diagnostics® to Present at Biotech Showcase™ 2012 During JP Morgan Healthcare Conference January 9 - 1210
. Saladax Biomedical, Inc. to Present at Biotech Showcase™ 201211
. Selexis SA to Present at Biotech Showcase 2012
(Date:9/1/2015)... Boston, MA (PRWEB) , ... September 01, 2015 ... ... from top biopharmaceutical companies in the neuro and pain management space join prominent ... Joseph B. Martin Conference Center at Harvard Medical School in Boston. , ...
(Date:9/1/2015)... Medfusion, Inc., a patient engagement ... and patients, today announced a $3 million investment ... venture capital firms. "We welcome ... City Venture Partners and Hatteras Venture Partners," said ... Chairman. "Both firms, experience working at the intersection ...
(Date:9/1/2015)... ... September 01, 2015 , ... A new ... by researchers at the Keck Graduate Institute and its collaborators. The discovery has ... findings were published online on August 27 by Scientific Reports, an open access ...
(Date:9/1/2015)... ... 01, 2015 , ... GenoCAD, a leading provider of DNA ... its flagship DNA design platform, which has been enhanced to boost user productivity. ... parts, which in turn can be recombined using specific sets of rules to ... Breaking Biology Technology:Neuro Advance Boston Brings Together Leading Neuroscience Experts on October 14 at Harvard Medical School 2Medfusion Secures Funding to Continue Evolution and Advance Mobile Strategy 2Medfusion Secures Funding to Continue Evolution and Advance Mobile Strategy 3Scientists Discover New Use for an Old Therapy Inhibiting Deadly Pathogens Including Ebola and Anthrax 2Scientists Discover New Use for an Old Therapy Inhibiting Deadly Pathogens Including Ebola and Anthrax 3Scientists Discover New Use for an Old Therapy Inhibiting Deadly Pathogens Including Ebola and Anthrax 4GenoCAD Releases Combinatorial Design Tool to Optimize Protein Expression and Streamline DNA Synthesis Orders 2
(Date:8/20/2015)... 20, 2015 The wearable technology market ... active and healthy. However, wearable technology has the ... to help improve diagnostic capabilities and therapeutic outcomes. ... Wearable Technologies Conference 2015 , where ... wearables in healthcare. "Over the ...
(Date:8/18/2015)... -- Research and Markets ( http://www.researchandmarkets.com/research/9dmm6l/global_biometric ) has ... Authentication & Identification Market: Focus On Modality, Motility ... report to their offering. The ... expected to grow at an estimated CAGR of ... $25 billion (approximately) by 2020 as per the ...
(Date:8/12/2015)... SAN JOSE, Calif. , Aug. 12, 2015 ... leading developer of human interface solutions, today announced ... the recently announced Match-in-Sensor solution, have officially been ... (FIDO) Alliance. As part of the certification, Synaptics, ... the FIDO 1.0 Universal Authentication Framework (UAF) standard ... Breaking Biology News(10 mins):Leaf Healthcare Releases Video from Wearable Technology Conference on New Applications for Wearables in the Hospital Environment 2Leaf Healthcare Releases Video from Wearable Technology Conference on New Applications for Wearables in the Hospital Environment 3Global Biometric Authentication & Identification Market 2015: Focus On Modality, Motility & Application - Estimation & Forecasts to 2020 for the $25 Billion Industry 2Synaptics Announces FIDO Certification of Natural ID Fingerprint Solutions 2Synaptics Announces FIDO Certification of Natural ID Fingerprint Solutions 3
OmniSlide Heated Wash Module. 2 independent chambers with precise temperature control from ambient of 5C to 70C. Each chamber holds 1 slide rack (20 slides). Includes 2 x Wash Sleeves, 1 x Slide R...
For cleavage of 6xHis tags from proteins containing a Factor Xa Protease recognition site Efficient 6xHis tag cleavage (greater than 90%), ...
... PBL's bioassays for interferons are cytopathic effect inhibition ... Sample types include; tissue culture supernatents; serum ... these assays, one unit is defined as the ... the cytopathic effect of viral infection by 50%. ...Biology Products: